Humacyte, Inc. (HUMA) Market Cap & Valuation Ratios
Humacyte, Inc. (HUMA) has a market cap of $121.0M and a price-to-sales ratio of 57.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HUMAHumacyte, Inc.Follow HUMA — free
—
Price chart with a free account
- Market cap
- 121.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| HUMA | 0.1 | — | 36.5 | — | — | +159% | — | — |
| CHRS | 0.2 | — | 1.7 | — | — | +61% | -312% | — |
| MDWD | 0.2 | — | 12.6 | — | — | -40% | -268% | -126% |
| UPB | 0.2 | — | — | — | — | +16% | — | -61% |
| RNA | 0.1 | — | — | — | — | — | — | — |
| CDXS | 0.1 | — | 1.6 | — | -8.7% | +36% | -36% | -48% |
| CMPX | 0.1 | — | — | — | — | — | — | -81% |
| NKTX | 0.1 | — | — | — | — | — | — | -50% |
| AVXL | 0.1 | — | — | — | — | — | — | — |
| VYGR | 0.1 | — | — | — | — | -19% | -340% | -74% |
| LENZ | 0.1 | — | 3.5 | — | — | — | — | -75% |
| Median of these 10 | — | 2.6 | — | -8.7% | +16% | -290% | -74% |
; EV/Sales 36.5 vs. 2.6.
Growth vs. price
each dot a company · hover or tap for valuesHumacyte, Inc. — questions
- What is Humacyte, Inc.'s market cap?
- $121.0M.
- What is Humacyte, Inc.'s price-to-sales ratio?
- 57.0.
Every figure on this page comes from Humacyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.